Redfern JS - Search Results

1

Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.

Chapman MJ, Redfern JS, McGovern ME, Giral P. Chapman MJ, et al. Among authors: redfern js. Pharmacol Ther. 2010 Jun;126(3):314-45. doi: 10.1016/j.pharmthera.2010.01.008. Epub 2010 Feb 11. Pharmacol Ther. 2010. PMID: 20153365 Review.

2

Optimal pharmacotherapy to combat the atherogenic lipid triad.

Chapman MJ, Redfern JS, McGovern ME, Giral P. Chapman MJ, et al. Among authors: redfern js. Curr Opin Cardiol. 2011 Sep;26(5):403-11. doi: 10.1097/HCO.0b013e32834965e9. Curr Opin Cardiol. 2011. PMID: 21730827 Review.

3

[Serum uric acid--a cardiovasular risk factor?].

Alderman M, Redfern JS. Alderman M, et al. Among authors: redfern js. Ther Umsch. 2004 Sep;61(9):547-52. doi: 10.1024/0040-5930.61.9.547. Ther Umsch. 2004. PMID: 15493113 Review. German.

4

Psoriasis in People With Skin of Color: An Evidence-Based Update.

Gkini MA, Nakamura M, Alexis AF, Londoño-Garcia A, van de Kerkhof PCM, Doss N, Griffiths CEM, Kaufman B, Kleyn CE, Lebwohl M, Redfern JS, Takeshita J, Rajagopalan M, El Sayed MH. Gkini MA, et al. Among authors: redfern js. Int J Dermatol. 2025 Apr;64(4):667-677. doi: 10.1111/ijd.17651. Epub 2025 Jan 31. Int J Dermatol. 2025. PMID: 39887710 Free PMC article. Review.

5

The Evolving Role of Pharmacists in Transgender Health Care.

Redfern JS, Jann MW. Redfern JS, et al. Transgend Health. 2019 Apr 11;4(1):118-130. doi: 10.1089/trgh.2018.0038. eCollection 2019. Transgend Health. 2019. PMID: 31289749 Free PMC article. Review.

6

Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America.

de la Cruz C, de Carvalho AV, Dorantes GL, Londoño Garcia AM, Gonzalez C, Maskin M, Podoswa N, Redfern JS, Valenzuela F, van der Walt J, Romiti R. de la Cruz C, et al. Among authors: redfern js. J Dermatol. 2017 Jan;44(1):3-12. doi: 10.1111/1346-8138.13512. Epub 2016 Jul 27. J Dermatol. 2017. PMID: 27461455 Review.

7

Psychosocial, HIV, and health care management issues impacting transgender individuals.

Redfern JS, Barnes A, Chang J. Redfern JS, et al. Am J Orthopsychiatry. 2016;86(4):366-72. doi: 10.1037/ort0000190. Am J Orthopsychiatry. 2016. PMID: 27380150

8

Effects of renal insufficiency and hemodialysis on the pharmacokinetics of rofecoxib.

Gottesdiener K, Agrawal N, Porras A, Wong P, Rogers JD, Gertz BJ, Redfern JS, Marbury T. Gottesdiener K, et al. Among authors: redfern js. Am J Ther. 2003 Jul-Aug;10(4):252-8. doi: 10.1097/00045391-200307000-00004. Am J Ther. 2003. PMID: 12845388 Clinical Trial.

9

Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients.

Schwartz JI, Agrawal NG, Wong PH, Bachmann KA, Porras AG, Miller JL, Ebel DL, Sack MR, Holmes GB, Redfern JS, Gertz BJ. Schwartz JI, et al. Among authors: redfern js. J Clin Pharmacol. 2001 Oct;41(10):1120-30. doi: 10.1177/00912700122012616. J Clin Pharmacol. 2001. PMID: 11583481 Clinical Trial.

10

Renal effects of COX-2-selective inhibitors.

Brater DC, Harris C, Redfern JS, Gertz BJ. Brater DC, et al. Among authors: redfern js. Am J Nephrol. 2001 Jan-Feb;21(1):1-15. doi: 10.1159/000046212. Am J Nephrol. 2001. PMID: 11275626 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

42 results

Search Page

Filters